期刊文献+

影响肝母细胞瘤儿童术后生存的因素分析 被引量:5

Factor affecting survival of children with hepatoblastoma after operation
下载PDF
导出
摘要 目的分析影响肝母细胞瘤儿童术后生存期的网素。方法选择2003年1月~2010年3月于术治疗的肝母细胞瘤患儿76例,进行定期随访,统计术后5a生存率,并分析其影响因素。结果本组肝母细胞瘤儿童术后5a生存率为48.68%(37H6);在≤2岁、血清LDH水平〉240U/L、m清CRP水平〉10mg/L患儿,5a生存率分别为46.15%、35.90%、37.84%,明显低于〉2岁、血清LDH水平≤240U/L、血清CRP水平≤10mg,L患儿(分别为54.16%、62.16%、58.97%);血清AFP水平〉10000μg/L患儿5a生存率为10.71%,明显低于〈100μg/L、100~10000μg/L患儿的68.75%、71.88%;PretetⅠ期、Ⅱ期、Ⅲ期患者5a生存率分别为80%、55.56%、8.33%,病理分型胎儿型、胚胎型、混合型分别为60.98%、44.44%、23.53%,5a生存率均依次减低,组间差异有统计学意义(P〈0.05);血清AFP水平、Pretext分期、病理分型是影响肝母细胞瘤儿童术后生存期的独立危险因素(OR1=4.223,OR2=5.826,OR3=9.342,P〈0.05)。结论肝母细胞瘤儿童术后5a生存期仍较低,血清AFP水平、Pretext分期和病理分型是需要重点考虑的问题。
出处 《实用肝脏病杂志》 CAS 2016年第1期102-104,共3页 Journal of Practical Hepatology
关键词 肝母细胞瘤 儿童 生存期 影响因素 Hepatoblastoma Children Survival Influencing factors
  • 相关文献

参考文献20

  • 1Meyers RL, Czauderna P, Otte JB. Surgical treatment of hepato- blastoma. Pediatr Blood Cancer,2012,59(5):800-808.
  • 2Ismail H,Broniszczak D,Kalicihski P,et al.Changing treatment and outcome of children with hepatoblastoma: analysis of a single center experience over the last 20 years.J Pediatr Surg, 2012,47(7 ) : 1331-1339.
  • 3张伟令,张谊,黄东生,洪亮,王一卓,朱霞,胡慧敏,张品伟,易优,韩涛.儿童晚期肝母细胞瘤综合治疗的疗效观察[J].中华实用儿科临床杂志,2013,28(7):521-524. 被引量:12
  • 4Gupta K,Rane S,Das A,et al. Relationship of beta-catenin and postchemotherapy histopathologic changes with overall survival in patients with hepatoblastoma. J Pediatr Hematol Oncol,2012,34(8):320-328.
  • 5胡亚美 江载芳.诸福棠实用儿科学7版[M].北京:人民卫生出版社,2002.441.
  • 6Zsiros J,Brugieres L,Brock P,et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high risk hepato- blastoma (SIOPEL4):a prospective,single-arm,feasibility study. Lancet Oncol,2013,14(9) :834-842.
  • 7Tsay PK,Lai PK,Yang CP,et al.Treatment outcomes for hepato- blastoma:Experience of 35 cases al a single institution.J Formos Med Assoc., 2011,110(5 ) :322-325.
  • 8Arora RS.Outcomes of hepatoblastoma in the Indian context.In- dian Pediatrics,2012,49(4) :307-309.
  • 9Barrena S,Hernandez F,Mignel M,et at.High-risk hepatoblas- toma:rcsuhs in a pediatric liver transplantation centcr.Eur J Pediatr Surg, 2011,21 ( l ) : 18-20.
  • 10Sail MW,Li J,Lamb L,et al. First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second- line therapy in patients with advanced pancreatic cancer. Can- cer Chemother Pharmacol,2014,73(2):373-380.

二级参考文献67

  • 1王甘露,李晓平,廖彩仙.肝母细胞瘤的诊断与治疗[J].临床和实验医学杂志,2006,5(6):707-708. 被引量:9
  • 2Leal-Leal CA, Imaz-Olguin V, Robles-Castro J, et al. Hepato- blastoma. Clinical experience at a single institution using the Siopel staging system. Ann Hepatol,20,10,9(l ):75 79.
  • 3Douglass EC, Reynolds M, Finegold M, et al. Cisplatin, vincris- tine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol, 1993,11 ( 1 ) : 96-99.
  • 4Ortega JA, Douglass EC, Feusner JH, et al. Randomized com- parison of cisplatin/vincristine/fluorouracil and cisplatin/con- tinuous infusion doxorubicin for treatment of pediatric hepato- blstoma, a report from the Children's Cancer Group and the Pe-diatric Oncology Group. J Clin Oncol, 2000, 18 (14) - 2665- 2675.
  • 5Aronson I3(2,sohnater JM,Staalman CR, et al. Predictive value of the pretreatment extent of disease system in hepatoblasto- ma: results from the International Society of Pediatric Oneolo- gy Liver Tumor Study Group SIOPEL-1 study. J Clin Oncol, 2005,23(6) : 1245-1252.
  • 6Darbari A, Sabin KM, Shapiro CN, et al. Epidemiology of pri- mary hepatic malignancies in U. S. children. Hepatology, 2003,38 (3) - 560-566.
  • 7Haas JE, Muczynski KA, Krailo M, et al. Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer, 1989,64(5) : 1082-1095.
  • 8Pham TH, Iqbal CW, Grams JM, et al. Outcomes of primary liver cancer in children: an appraisal of experience. J Pediatr Surg,2007,42(5) : 834-839.
  • 9Brown J,Perilongo G,Shafford E, et al. Pretreatment prognos- tic factors for children with hepatoblastoma--results from the International Society of Paediatric Oncology(SIOP) study SIO- PEL 1. Eur J Cancer,2000,36( 11 ) - 1418-1425.
  • 10Evans AE, Land VJ, Newton WA, et al. Combination chemo- therapy (vincristine, Adriamycin, cyclophosphamide, and 5-flu orouracil) in the treatment of children with malignant hepato- ma. Cancer, 1982,50(5) : 821-826.

共引文献191

同被引文献34

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部